Abstract
With advances in nanotechnology, it is now possible to develop highly specific and effective treatments for a myriad of important human diseases including cancer and cardiovascular and inflammatory diseases. One important obstacle in the development of safer and more effective therapeutics has been the challenge of delivering drugs to the site of action at an optimal exposure and rate. The design and development of biocompatible, targeted nanoparticles that control the release of drugs at the site of interest has the potential to revolutionize drug development and enable entirely new therapeutic approaches such as RNA interference (RNAi). This chapter gives an insight into the development of nanoparticle platforms for the targeted and temporally controlled delivery of drugs with minimal off target effects and reviews the available classes of ligands for targeting applications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303:1818–1822
Wagner V, Dullaart A, Bock A-K, Zweck A (2006) The emerging nanomedicine landscape. Nat Biotechnol 24(10):1211–1217
Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3(1):16–20
Petros RA, DeSimone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9(8):615–627
Shi J, Votruba AR, Farokhzad OC, Langer R (2010) Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 10(9):3223–3230
Cai W, Chen X (2007) Nanoplatforms for targeted molecular imaging in living subjects. Small 3(11):1840–1854
Gao X et al (2005) In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol 16(1):63–72
Davis ME, Chen Z, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7(9):771–782
Zhang L et al (2007) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83(5):761–769
Heath T, Fraley R, Papahdjopoulos D (1980) Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab′)2 to vesicle surface. Science 210:539–541
Leserman LD, Barbet J, Kourilsky F, Weinstein JN (1980) Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 288:602–604
Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207
Chan JM et al (2010) Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci USA 107(5):2213–2218
Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC (2011) Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 108(5):1850–1855
Rothenfluh DA, Bermudez H, O’Neil CP, Hubbell JA (2008) Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat Mater 7(3):248–254
Georgieva JV et al (2011) Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood–brain barrier endothelial cells in vitro. Mol Ther 19(2):318–325
Farokhzad OC, Langer R (2006) Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 58(14):1456–1459
Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54(5):631–651
Wang AZ et al (2008) Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 8(8):1063–1070
Ganta S, Devalapally H, Shahiwala A, Amiji M (2008) A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 126(3):187–204
Kale AA, Torchilin VP (2010) Environment-responsive multifunctional liposomes. Methods Mol Biol 605:213–242
Oh KT, Yin H, Lee ES, Bae YH (2007) Polymeric nanovehicles for anticancer drugs with triggering release mechanisms. J Mater Chem 17(38):3987–4001
Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future prospects. FASEB J 19(3):311–330
Antimisiaris SG, Kallinteri P, Fatouros DG (2007) Liposomes and drug delivery. Wiley, New York, pp 443–533
Moghimi SM, Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42(6):463–478
Chowdhery R, Gonzalez R (2011) Immunologic therapy targeting metastatic melanoma: Allovectin-7. Immunotherapy 3(1):17–21
Matsumura Y et al (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 15(3):517–525
Sankhala KK, Mita AC, Adinin R, Wood L, Beeram M, Bullock S, Yamagata N, Matsuno K, Fujisawa T, Phan AT (2009) A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. J Clin Oncol 27(15S):2535
Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP (2004) Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release 100(1):135–144
Schiffelers RM et al (2003) Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 91(1–2):115–122
Pan XQ et al (2002) Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100(2):594–602
Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4(2):145–160
Greco F, Vicent MJ (2009) Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 61(13):1203–1213
Bae Y et al (2004) Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem 16(1):122–130
Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC (2010) Polymeric nanoparticles for drug delivery. Methods Mol Biol 624:163–175
Napier ME, DeSimone JM (2007) Nanoparticle drug delivery platform. Polym Rev 47(3):321–327
Matsumura Y, Kataoka K (2009) Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 100(4):572–579
Sutton D, Nasongkla N, Blanco E, Gao J (2007) Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 24(6):1029–1046
Matsumura Y, Phase I (2004) Clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91:1775–1781
Hamaguchi T et al (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 92(7):1240–1246
Wilson RHP, Adam R, Eatock J, Boddy MM, Griffin AV, Miller MR, Matsumura Y, Shimizu T, Calvert V (2008) Phase I and pharmacokinetic study of NC-6004, a new platinum entity of cisplatin-conjugated polymer forming micelles. J Clin Oncol (Meeting Abstracts) 26:2573
Hamaguchi T et al (2010) Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res 16(20):5058–5066
Kim T-Y et al (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10(11):3708–3716
Lee KS et al (2006) Multicenter phase II study of a cremophor-free polymeric micelle-formulated paclitaxel in patients with metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 24(18_suppl):10520
Alexis F et al (2008) HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem 3(12):1839–1843
Farokhzad OC et al (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103(16):6315–6320
Gao W, Chan JM, Farokhzad OC (2010) pH-responsive nanoparticles for drug delivery. Mol Pharm 7(6):1913–1920
Zhang L et al (2007) Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2(9):1268–1271
Farokhzad OC et al (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64(21):7668–7672
Gu F et al (2008) Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 105(7):2586–2591
Service RF (2010) Nanoparticle Trojan horses gallop from the lab into the clinic. Science 330:314–315
Chan JM et al (2009) PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30(8):1627–1634
Salvador-Morales C, Zhang L, Langer R, Farokhzad OC (2009) Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 30(12):2231–2240
Valencia PM et al (2010) Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano 4(3):1671–1679
Wang AZ et al (2010) ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine 5(3):361–368
Zhang L et al (2008) Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2(8):1696–1702
Sengupta S et al (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436:568–572
Paleos CM, Tsiourvas D, Sideratou Z, Tziveleka LA (2010) Drug delivery using multifunctional dendrimers and hyperbranched polymers. Expert Opin Drug Deliv 7(12):1387–1398
Lee CC, MacKay JA, Frechet JMJ, Szoka FC (2005) Designing dendrimers for biological applications. Nat Biotech 23(12):1517–1526
Liu M, Kono K, Frechet JMJ (2000) Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Rel 65(1–2):121–131
Xu Q, Wang CH, Pack DW (2010) Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers. Curr Pharm Des 16(21):2350–2368
Gillies ER, Jonsson TB, Frechet JMJ (2004) Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers. J Am Chem Soc 126(38):11936–11943
McCarthy TD et al (2005) Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2(4):312–318
Padilla De Jesus OL, Ihre HR, Gagne L, Frechet JMJ, Szoka FC Jr (2002) Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem 13(3):453–461
Patri AK, Kukowska-Latallo JF, Baker JR (2005) Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 57(15):2203–2214
Yellepeddi VK, Kumar A, Palakurthi S (2009) Surface modified poly(amido)amine dendrimers as diverse nanomolecules for biomedical applications. Expert Opin Drug Deliv 6(8):835–850
Kukowska-Latallo JF et al (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65(12):5317–5324
Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5(4):505–515
Owens DE III, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307(1):93–102
Eisenstein M (2006) Protein arrays: growing pains. Nature 444:959–962
Ostuni E, Chapman RG, Holmlin RE, Takayama S, Whitesides GM (2001) A survey of structure–property relationships of surfaces that resist the adsorption of protein. Langmuir 17(18):5605–5620
Nagayama S, Ogawara K-I, Fukuoka Y, Higaki K, Kimura T (2007) Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm 342(1–2):215–221
Fang C et al (2006) In vivo tumor targeting of tumor necrosis factor-[alpha]-loaded stealth nanoparticles: effect of mPEG molecular weight and particle size. Eur J Pharm Sci 27(1):27–36
Yuan F et al (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55(17):3752–3756
Kong G, Braun RD, Dewhirst MW (2000) Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 60(16):4440–4445
Roser M, Fischer D, Kissel T (1998) Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 46(3):255–263
Schwendener RA, Lagocki PA, Rahman YE (1984) The effects of charge and size on the interaction of unilamellar liposomes with macrophages. Biochim Biophys Acta (BBA) - Biomembranes 772(1):93–101
Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6(3):659–668
Knop K, Hoogenboom R, Fischer D, Schubert US (2010) Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed 49(36):6288–6308
Vonarbourg A, Passirani C, Saulnier P, Benoit J-P (2006) Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27(24):4356–4373
Gref R et al (2000) ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 18(3–4):301–313
Moghimi SM, Porter CJH, Illum L, Davis SS (1991) The effect of Poloxamer-407 on liposome stability and targeting to bone marrow: comparison with polystyrene microspheres. Int J Pharm 68(1–3):121–126
Takae S et al (2005) Ligand density effect on biorecognition by PEGylated gold nanoparticles: regulated interaction of RCA120 lectin with lactose installed to the distal end of tethered PEG strands on gold surface. Biomacromolecules 6(2):818–824
Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10):750–763
Torchilin VP (2008) Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv 5:1003–1025
Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19(4):424–436
Nellis DF et al (2005) Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog 21(1):205–220
Nobs L, Buchegger F, Gurny R, Allemann E (2004) Poly(lactic acid) nanoparticles labeled with biologically active neutravidin for active targeting. Eur J Pharm Biopharm 58(3):483–490
Patri AK et al (2004) Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 15(6):1174–1181
Brennan FR, Shaw L, Wing MG, Robinson C (2004) Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges. Mol Biotechnol 27(1):59–74
Weinberg WC et al (2005) Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev 24(4):569–584
Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1(2):118–129
Pavlinkova G et al (2001) Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs. Int J Cancer 94(5):717–726
Mebiopharm Co., Ltd (2009) Safety study of MBP-426 (liposomal oxaliplatin suspension for injection) to treat advanced or metastatic solid tumors. http://clinicaltrials.gov/ct2/show/NCT00355888. Accessed on May 8, 2011
SynerGene Therapeutics, Inc. (2010) Safety study of infusion of SGT-53 to treat solid tumors. http://clinicaltrials.gov/ct2/show/NCT00470613. Accessed on May 8, 2011
Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818–822
Fang X, Tan W (2010) Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res 43(1):48–57
Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–510
Farokhzad OC, Karp JM, Langer R (2006) Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 3(3):311–324
Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC (2008) Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 26(8):442–449
Nimjee SM, Rusconi CP, Sullenger BA (2005) Aptamers: an emerging class of therapeutics. Annu Rev Med 56:555–583
Potti A, Rusconi CP, Sullenger BA, Ortel TL (2004) Regulatable aptamers in medicine: focus on antithrombotic strategies. Expert Opin Biol Ther 4(10):1641–1647
Shangguan D et al (2006) Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 103(32):11838–11843
Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L (2003) A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 100(26):15416–15421
Ng EW et al (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5(2):123–132
Bagalkot V et al (2007) Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 7(10):3065–3070
Kim D, Jeong YY, Jon S (2010) A drug-loaded aptamer—gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 4(7):3689–3696
Kolishetti N et al (2010) Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 107(42):17939–17944
Cheng JJ et al (2007) Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5):869–876
Chiu T-C, Huang C-C (2009) Aptamer-functionalized nano-biosensors. Sensors 9(12):10356–10388
Delehanty JB, Boeneman K, Bradburne CE, Robertson K, Medintz IL (2009) Quantum dots: a powerful tool for understanding the intricacies of nanoparticle-mediated drug delivery. Expert Opin Drug Deliv 6(10):1091–1112
Huang Y-F, Sefah K, Bamrungsap S, Chang H-T, Tan W (2008) Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir 24(20):11860–11865
Lam KS et al (1991) A new type of synthetic peptide library for identifying ligand-binding activity. Nature 354:82–84
Needels MC et al (1993) Generation and screening of an oligonucleotide-encoded synthetic peptide library. Proc Natl Acad Sci USA 90(22):10700–10704
McGuire MJ, Li S, Brown KC (2009) Biopanning of phage displayed peptide libraries for the isolation of cell-specific ligands. Methods Mol Biol 504:291–321
Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380:364–366
Arap W et al (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8(2):121–127
Lam KS, Zhao ZG (1997) Targeted therapy for lymphoma with peptides. Hematol Oncol Clin North Am 11(5):1007–1019
Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC (2007) Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 67(22):10958–10965
Chang DK, Lin CT, Wu CH, Wu HC (2009) A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS ONE 4(1):e4171
Li J et al (2004) Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor. Cancer Gene Ther 11(5):363–370
Ruoslahti E, Pierschbacher M (1987) New perspectives in cell adhesion: RGD and integrins. Science 238:491–497
Danhier F et al (2009) Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. J Control Release 140(2):166–173
Ohannesian DW et al (1995) Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res 55(10):2191–2199
Zubieta MR et al (2006) Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 168(5):1666–1675
David A, Kopeckova P, Kopecek J, Rubinstein A (2002) The role of galactose, lactose, and galactose valency in the biorecognition of N-(2-hydroxypropyl)methacrylamide copolymers by human colon adenocarcinoma cells. Pharm Res 19(8):1114–1122
Managit C, Kawakami S, Nishikawa M, Yamashita F, Hashida M (2003) Targeted and sustained drug delivery using PEGylated galactosylated liposomes. Int J Pharm 266(1–2):77–84
Ross JF, Chaudhuri PK, Ratnam M (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73(9):2432–2443
Stella B et al (2000) Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci 89(11):1452–1464
Park EK, Lee SB, Lee YM (2005) Preparation and characterization of methoxy poly(ethylene glycol)/poly([ epsilon]-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials 26(9):1053–1061
Liu Y, Li K, Pan J, Liu B, Feng S-S (2010) Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials 31(2):330–338
Ni S, Stephenson SM, Lee RJ (2002) Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res 22(4):2131–2135
Pan XQ, Wang H, Lee RJ (2003) Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res 20(3):417–422
Stephenson SM et al (2003) Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Anticancer Res 23(4):3341–3345
Low PS, Henne WA, Doorneweerd DD (2007) Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41(1):120–129
Zhao X, Li H, Lee RJ (2008) Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 5(3):309–319
Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L (2005) Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 23(11):1418–1423
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Swami, A., Shi, J., Gadde, S., Votruba, A.R., Kolishetti, N., Farokhzad, O.C. (2012). Nanoparticles for Targeted and Temporally Controlled Drug Delivery. In: Svenson, S., Prud'homme, R. (eds) Multifunctional Nanoparticles for Drug Delivery Applications. Nanostructure Science and Technology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-2305-8_2
Download citation
DOI: https://doi.org/10.1007/978-1-4614-2305-8_2
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-2304-1
Online ISBN: 978-1-4614-2305-8
eBook Packages: EngineeringEngineering (R0)